U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Shekelle P, Morton S, Rich M, et al. Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction: Effect in Female, Black, and Diabetic Patients, and Cost-Effectiveness. Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Jul. (Evidence Reports/Technology Assessments, No. 82.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction

Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction: Effect in Female, Black, and Diabetic Patients, and Cost-Effectiveness.

Show details

References

1.
American Heart Association. 1998 Heart and stroke statistical update. Dallas: American Heart Association; 1997.
2.
Materson B J, Reda D G, Cushman W C. et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914. [PubMed: 8446138]
3.
Yusuf S, Nicklas J M, Timmis G. et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992;327:685–691. [PubMed: 1463530]
4.
Limacher MC, Yusuf S. Cardiovascular health and disease in women. In: Wenger, Speroff, Packard (eds): Proceedings of an NHLBI Conference. Darien:LeJacq; 1993.
5.
Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven Publishers; 1998.
6.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. [PubMed: 3802833]
7.
Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego: Academic Press, Inc.; 1985.
8.
Stata Corporation. Stata Statistical Software. Release 7.0. College Station: Stata Corporation; 2001.
9.
Parmar M K, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–2834. [PubMed: 9921604]
10.
SAS Institute, Inc. SAS/STAT. Cary, NC: SAS Institute, Inc.; 1999.
11.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. [PMC free article: PMC2127453] [PubMed: 9310563]
12.
Begg C B, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101. [PubMed: 7786990]
13.
Fryback D G, Dasbach E J, Klein R. et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89–102. [PubMed: 8483408]
14.
U.S. Bureau of the Census. Statistical abstract of the United States. U.S. Census Bureau: Washington;2000.
15.
Bureau of Labor Statistics. Consumer price index. http://www​.bls.gov/cpi/home.htm.
16.
AAUP policy documents and reports (The Redbook). Baltimore: Johns Hopkins University Press; 2001.
17.
Paul S D, Kuntz K M, Eagle K A, Weinstein M C. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med. 1994;154:1143–9. [PubMed: 8185426]
18.
Gold M, Siegel J, Russel L, Weinstein M (eds.). Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
19.
National Center for Health Statistics. United States life tables, 1998 (PHS 2000-1120). Atlanta: Centers for Disease Control and Prevention; 2000. [PubMed: 11227258]
20.
McDonagh T A, Robb S D, Murdoch D R, Morton J J, Ford I, Morrison C E, Tunstall-Pedoe H, McMurray J J V, Dargie H J. N Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9–13. [PubMed: 9433422]
21.
McDonagh T A, Morrison C E, Lawrence A. et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829–33. [PubMed: 9310600]
22.
Naik M M, Diamond G A, Pai T. et al. Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography. J Am Coll Cardiol. 1995;25:937–42. [PubMed: 7884101]
23.
Schiller N B, Acquatella H, Ports T A. et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation. 1979;60:547–55. [PubMed: 455617]
24.
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302. [PubMed: 2057034]
25.
National Center for Health Statistics. Vital Statistics of the United States: Mortality. Atlanta: Centers for Disease Control and Prevention; 1991.
26.
American Heart Association. Heart and stroke statistical update. Dallas: American Heart Association; 2000.
27.
Glick H, Cook J, Kinosian B. et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) treatment trial. J Cardiac Failure. 1995;1:371–380. [PubMed: 12836712]
28.
Cook J R, Glick H A, Gerth W. et al. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. Am J Hypertens. 1998;11:1433–41. [PubMed: 9880125]
29.
Ball S G, Hall A S, Mackintosh A F. et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342(8875):821–8. [PubMed: 8104270]
30.
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35. [PubMed: 2883575]
31.
Pfeffer M A, Braunwald E, Moye L A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77. [PubMed: 1386652]
32.
Moye L A, Pfeffer M A, Wun C C. et al. Uniformity of captopril benefit in the SAVE study: subgroup analysis. Eur Heart J. 1994;15:2–8. [PubMed: 8076658]
33.
Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80–85. [PubMed: 7990904]
34.
Exner D V, Dries D L, Domanski M J, Cohn J N. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Eng J Med. 2001;344:1351–7. [PubMed: 11333991]
35.
Kober L, Torp-Pedersen C, Carlsen J E. et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333(25):1670–6. [PubMed: 7477219]
36.
The Beta-Blocker Evaluation of Survival Trial Investigators (BEST): a trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659–67. [PubMed: 11386264]
37.
Eichhorn E J, Domanski M J, Adams K. et al. Effect of beta-blockade on mortality in African-Americans: the beta-blocker evaluation of survival trial. Circulation. 2000;102(suppl 2):18.
38.
Plehn J F, Krause-Steinrauf H, Anand I S. et al. Effect of race on cause-specific cardiovascular mortality in BEST. Circulation. 2000;102(suppl 2):18.
39.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13. [PubMed: 10023943]
40.
Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Euro J Heart Failure. 2001;3:469–479. [PubMed: 11511434]
41.
Packer M, Coats A J S, Fowler M B. et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8. [PubMed: 11386263]
42.
Hjalmarson A, Goldstein S, Fagerberg B. et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007. [PubMed: 10376614]
43.
Wedel H, DeMets D, Deedwania P. et al. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HR trial. Am Heart J. 2001;142:502–11. [PubMed: 11526365]
44.
Ghali J K, Pina I L, Gottlieb S S. et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002;105:1585–91. [PubMed: 11927527]
45.
Packer M, Bristow M R, Cohn J N. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55. [PubMed: 8614419]
46.
Yancy C W, Fowler M B, Colucci W S. et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358–65. [PubMed: 11333992]

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...